Access Q&A

Do not assume that a product listing, a shipment option, or an informal description of Dutch practice establishes legality. The position may depend on the substance, its form, intended use, and the facts of a particular case. Dutch medicines oversight includes assessment of medicines and their authorization; the Medicines Evaluation Board is an official starting point for questions about medicines regulation.

Further verification: Ask the CBG-MEB which current legal framework is relevant to the product and intended use. For an import question, ask the competent customs or regulatory authority what written documentation it would require; retain the reply rather than relying on marketing language.

A clinic’s statement that it can provide an intervention does not, by itself, establish authorization, clinical appropriateness, or safety. Ask what legal and clinical basis it relies on, who holds responsibility for assessment and decision-making, and how urgent complications are handled. The clinical risk and guidance overview explains why screening, medication review, monitoring, and escalation planning should not be treated as minor details.

Further verification: Request written information on the intervention, responsible clinician, screening approach, emergency transfer arrangements, complaints process, and privacy handling. For questions about care-provider oversight, check the remit and published information of the Health and Youth Care Inspectorate.

Coverage is not something to infer from a provider’s price quote, an invoice, or a claim that a service is therapeutic. It may depend on the exact policy, the benefit rules, the provider’s status, prior authorization, and the care involved. The National Health Care Institute publishes information about the Dutch health-care system and insured care, but an individual insurer remains the right source for a policy decision.

Further verification: Ask your insurer, in writing, whether the specific proposed care is covered, what documents it needs, whether prior authorization applies, and whether any reimbursement limit or provider condition applies. Keep the response with the policy terms.

Look for claims that can be checked, not merely reassuring language. A provider should be able to explain what is being offered, what evidence it relies on, who is accountable for care, how risks are assessed, and what happens if a complication occurs. A useful comparison point is the Dutch legal primer, which separates a general regulatory question from a promise that a particular service is authorized or suitable.

Further verification: Request documents rather than summaries: terms of care, consent materials, safety protocols, clinician responsibility, complaint procedures, and any claimed authorization. If a claim relates to a medicine, ask the CBG-MEB which register or decision would substantiate it; if it concerns regulated care, ask the IGJ what route is appropriate for verification.

Keep questions specific and document-focused. Ask: Which rule or authorization is relevant? What is the status of the product or intervention? Who has clinical responsibility? What contraindications, interactions, and emergency pathways are considered? Which written records can support the answer? The discussion of how this resource frames legal and safety questions may help you distinguish a request for verifiable information from a request for personal legal or medical advice.

Further verification: Direct medicine-status questions to the CBG-MEB, questions about care oversight to the IGJ, and coverage questions to the insurer. If a response is material to a decision, ask for the relevant policy, register entry, authorization, or written confirmation.